Lantern Pharma (LTRN) Tops Q4 EPS by 16c

Lantern Pharma (NASDAQ: LTRN) reported Q4 EPS of ($0.31), $0.16 better than the analyst estimate of ($0.47).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• SpaceX: New Street Research sees 22% upside from proposed IPO price
• General Dynamics upgraded to Buy as submarine boom fuels growth outlook
• Generac Holdings (GNRC) PT Raised to $335 at UBS on durability and visibility of earnings trajectory